Hanmi acquired approval of ‘Amosartan Plus,’ 3-substance combination therapy for treatment of hypertension

Published: 2017-07-06 13:07:10

Updated: 2017-07-06 13:07:10

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) announced ‘Amosartan Plus,’ a 3-substance combination drug for the treatment of hypertension, acquired commercialization approval from the Ministry of Health and Welfare(MOHW) on the 29^th.

Amosartan Plus, the world’s first global combination drug of 3 substances, amlodipine camsylate, losartan potassium and chlortalidone, acquired approval as an in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.